Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's disease
about
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's disease
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@ast
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@en
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@en-gb
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@nl
type
label
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@ast
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@en
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@en-gb
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@nl
prefLabel
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@ast
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@en
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@en-gb
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@nl
P2093
P2860
P921
P1476
Non-ergot dopamine agonists an ...... actions in Parkinson's disease
@en
P2093
Allison W Willis
Dafna E. Kohen
Donald R. Mattison
James A.G. Crispo
Lindsey Sikora
Lise M Bjerre
Renée C Hessian
Santiago Perez-Lloret
Yannick Fortin
P2860
P356
10.1002/14651858.CD011843
P577
2015-09-03T00:00:00Z